An in vitro comparison of different providers to deliver four proton pump inhibitor products through a feeding tube.
BACKGROUND
It is unclear how delivery through a feeding tube compares between esomeprazole in water, lansoprazole oral disintegrating tablet in water, omeprazole/NaHCO(3) in water and simplified lansoprazole suspension.


OBJECTIVE
This in vitro study compared delivery through a narrow calibre (8F) feeding tube among four proton pump inhibitors when given by skilled [nurse; (n = 8)] or unskilled [lay; (n = 8)] providers.


METHODS
Following standard instruction, subjects were observed delivering each proton pump inhibitor in a sequential, but random, fashion to evaluate administration quality and time. Delivery was quantified using high-performance liquid chromatography methods and subject preferences were evaluated.


RESULTS
Delivery (%), similar between lansoprazole oral disintegrating tablet (95.7 +/- 3.2) and omeprazole/NaHCO(3) (96.1 +/- 3.0), was both greater for lansoprazole oral disintegrating tablet than esomeprazole in water (88.9 +/- 8.6; P = 0.006) or simplified lansoprazole suspension (86.1 +/- 9.5; P = 0.0001) and omeprazole/NaHCO(3) than esomeprazole in water (P = 0.004) or simplified lansoprazole suspension (P < 0.001), and was not affected by prior subject experience. Quality was higher with both omeprazole/NaHCO(3) and lansoprazole oral disintegrating tablet than simplified lansoprazole suspension. Administration was quicker for lansoprazole oral disintegrating tablet than esomeprazole in water. Subjects preferred lansoprazole oral disintegrating tablet and omeprazole/NaHCO(3).


CONCLUSIONS
When given through an in vitro feeding tube, omeprazole/NaHCO(3) and lansoprazole oral disintegrating tablet lead to greater drug delivery, improved administration quality and higher user satisfaction, than either esomeprazole in water or simplified lansoprazole suspension.
Devlin
J W
JW
School of Pharmacy, Northeastern University, Boston, MA 02115, USA. j.devlin@neu.edu
Bakshi
A
A
Bungay
K
K
Olsen
K M
KM
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage*; D000284:Administration, Oral; D000328:Adult; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D064098:Esomeprazole; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage*; D017060:Patient Satisfaction / Q000706:statistics & numerical data; D054328:Proton Pump Inhibitors; D017494:Proton Pumps / Q000008:administration & dosage
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors; D017494:Proton Pumps; D064747:Lansoprazole; D009853:Omeprazole; D064098:Esomeprazole